Andrew Edge

Prix à l'honneur

Legal 500 UK 2026

Hall of fame in the M&A: lower mid-market deals, £100m-£750m category

Andrew is a senior M&A and equity capital markets lawyer with extensive experience in public and private mergers and acquisitions, IPOs and secondary offerings, joint ventures and private financing rounds.

He is one of only six London lawyers to be ranked in Tier 1 for mid-market M&A by Chambers UK legal directory as well as being listed as one of The Lawyer's Hot 100. As quoted in the legal directories, Andrew's clients describe him as 'a strong negotiator and problem solver' as well as being 'Incredibly pragmatic. The perfect sounding board for our business.'

Andrew is the UK Head of Corporate Life Sciences and is recognised within the legal directories as a 'very talented' corporate and commercial lawyer with a long-standing commitment to the biotechnology and pharmaceutical industries.

While at his previous firm, Andrew led the team on the contested public takeover of his long-standing client Lavendon Group plc, a transaction which garnered industry recognition at The Legal Business Awards.

CV

Since 2021 Partner, Taylor Wessing

2010 - 2021 Partner and Head of Corporate (2014 - 2020), Stephenson Harwood LLP

2002 - 2010 Partner, Ashurst LLP

Carrière

Since 2021 Partner, Taylor Wessing

2010 - 2021 Partner and Head of Corporate (2014 - 2020), Stephenson Harwood LLP

2002 - 2010 Partner, Ashurst LLP

Formation

1994 Admitted as a lawyer, England and Wales

1987 - 1990 University of Birmingham, LLB Law

Prix et distinctions

Legal 500 UK 2026

Featured

Legal 500 UK 2025

Chambers and Partners UK 2024

Experience

Market-leading work in the life sciences sector

We have won Life Sciences Team of the Year at the Legal Business Awards 2023 for advising on three simultaneous transformational transactions for AIM-listed Shield Therapeutics plc.

Press release

Shane Gleghorn

Andrew Edge

Adrian Toutoungi

Apollo Therapeutics closes $226.5 million series C financing

We advised Apollo Therapeutics in their USD226.5 million series C fundraising. Apollo aims to advance pipeline programs through clinical development and further fund the company’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, which include The Institute of Cancer Research.

Press release

Andrew Edge

Howard Palmer

Oli Denne

Charlie Adams